Novo Nordisk (NVO.N) said its long-acting growth hormone injection, marketed in
China as NuozeYou, received approval for three additional pediatric indications:
growth retardation associated with Noonan syndrome in children aged 2.5 years
and older; idiopathic short stature in children aged 2.5 years and older; and
children born small for gestational age who remain short at age 2, for treatment
in patients aged 2.5 years and older. The product was previously approved in
China for pediatric growth hormone deficiency.
